Share Name Share Symbol Market Type Share ISIN Share Description
Vectura Group LSE:VEC London Ordinary Share GB00B01D1K48 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.40p -2.91% 113.50p 113.40p 113.60p 117.60p 113.30p 116.90p 2,306,901 15:57:34
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 126.5 -40.1 -5.3 - 769.68

Vectura Share Discussion Threads

Showing 6476 to 6500 of 6500 messages
Chat Pages: 260  259  258  257  256  255  254  253  252  251  250  249  Older
DateSubjectAuthorDiscuss
18/1/2018
15:42
Does it ???
pooroldboy55
18/1/2018
15:20
chart looks ready to bounce a lot higher
chutes01
18/1/2018
09:59
Any bidder has a dilemma here. Does he bid before the advair situation is sorted, or after. If before then the share price will be lower anyway and he would still need to deliver a large premium to shareholders. If after then I can see a bidding war starting, as the other bidders will appear, wanting to increase there generic drug exposure.
jimboyce
18/1/2018
09:55
Although sometiems the repeat of the 'old' smoke is just people trying to re-hash something that didn't have substance behind it?
dunderheed
18/1/2018
09:53
No smoke without fire though? (Just saying.... beeen a bloody lot of smoke and repeat smoke).
dunderheed
18/1/2018
09:39
Sure if takeover price would not be falling back just a rumour me thinks.
pooroldboy55
18/1/2018
08:05
ok thanks. for me the combination of GSK and a possible offer of 175p was new (but i have not followed all the news about the rumours.
0815exitstrategy
18/1/2018
07:11
0815exitstrategy-no it's not, the report is based on the original DT rumour. With the share price under 120p it doesn't seem that too much credence is being given to the rumour, however I'm keeping my fingers crossed that something is going on.
alexchry
18/1/2018
07:00
Is a takeover getting more concrete? hxxps://www.fiercepharma.com/pharma/glaxosmithkline-eyes-1-7b-bid-for-respiratory-partner-vectura-report
0815exitstrategy
17/1/2018
09:33
They did buy over 600,000 last week but there had been no buying prior to that since before Christmas.
popper joe
17/1/2018
08:49
jimboyce-I did think that at first but brokers operate completely blindly to the company, they only have the information that all investors have so not sure why they have stopped at the moment.
alexchry
17/1/2018
08:42
No buy backs for the last few days. Is something brewing to stop the buy back?Have the brokers been put on hold?Rumours, rumours.
jimboyce
16/1/2018
10:47
Yes alex, it does look like a ham-fisted rehash of that story. Yet again today in what has become the norm recently, VEC struggling to hold any gains as the Auto trade seller/s quickly moves in at volume upon any buying off the orderbook.
s1zematters
16/1/2018
07:19
s1zematters-I was hoping it might be an independent source of the takeover rumour but it reads like it is based on the DT rumour with embellishments. Trade volumes are well above average but not sure whether it's because of the rumours or someone building a position, no RNS so far regarding change of holding.
alexchry
15/1/2018
23:40
yet more ventilation of a bid from Glaxo, this time at in the USA website pharmaphorum.com reading the story, it seems the editor is not familiar with vec or its financial position! hTTps://pharmaphorum.com/news/rumours-1-65bn-gsk-bid-respiratory-partners-vectura/ GlaxoSmithKline could be poised to acquire its respiratory partner, UK biotech Vectura, for $1.65bn. Speculation around a possible bid has mounted in recent months because GSK is about to face generic competition against its respiratory blockbuster Advair in the US – and also because Vectura has had to scale back its ambitions because of mounting debts. The Daily Telegraph newspaper reported late last week that GSK might bid £1.2bn ($1.65bn), a significant premium to Vectura’s current market capitalisation of £824 million. The biotech firm’s share price fell nearly 40% over the course of 2017, largely because the FDA had rejected Vectura and Hikma’s generic version of Advair, but the companies now hope to resolve these problems in Q1 this year. Vectura’s smart inhaler technology is used in GSK’s next-generation Ellipta respiratory products, and bringing it in house could boost the big pharma’s respiratory franchise. However Vectura’s many partnerships with GSK’s rivals could prove to be a stumbling block – as could the fact that Vectura is preparing to challenge GSK’s Advair with a generic challenger. Vectura also has collaborations with Mundipharma, Bayer and Novartis, and these partners have also been linked as possible buyers of the company. James Ward-Lilley Its financial problems led Vectura’s chief executive James Ward-Lilley to announce a new business strategy in early January. He unveiled a shift in its focus towards lower risk development opportunities in high potential generics molecules in its pipeline. It will also end new investment in higher risk, novel molecules in early stage programmes, and says it will look opportunities to partner existing programmes. These include its early stage novel molecule VR588 and VR942, an inhaled biologic which completed a Phase I trial during 2017 and which Vectura is already co-developing with UCB. The most promising late-stage project in its pipeline is the Novartis triple combination programme for asthma, QVM149. This is currently in a phase 3 trial, with first regulatory submissions expected in 2019. For GSK, a mid-sized acquisition would be a break from its recent past, as the company under previous CEO Sir Andrew Witty refrained almost entirely from M&A. However new chief executive Emma Walmsley is taking a different approach, and is also mulling a move for Pfizer’s multi-billion dollar consumer division, which could be up for sale later this year. 2018 is expected to see a major increase in pharma-biotech M&A, with Silicon Valley Bank predicting the year will see 20 ‘big exit’ deals over the year.
s1zematters
15/1/2018
21:29
Wow, 3.46 Million shares in one buy. There is definitely something going on.......
0815exitstrategy
15/1/2018
14:49
it's a strange situation, an aggressive buyer meeting an equally aggressive seller! Without that seller i suspect this would be in the 130's by now with the buying since Xmas week. Keep an eye on the close auction, in the last circa 12 close auctions it has ended below bid about 9 times as the seller piles stock onto the book for the UT. The close auction is usually a good sign of strength or weakness in a share, but despite this, VEC is holding up.
s1zematters
15/1/2018
14:42
Indeed, and as we know, once a company is named and it has substance, LSE rules would have forced an RNS.
s1zematters
15/1/2018
14:41
s1zematters-perhaps the fact that the same DT three weeks earlier had suggested Novartis were considering a takeover bid made investors even more sceptical about DT takeover rumours.
alexchry
15/1/2018
14:29
The paradox here is that there is both a persistent AT buyer and a very large AT seller in the market,hence it always gives back its day gains and usually ends below bid in the close auction as seller is prepared to take less for volume. One of the larger holders must be filling all these buys since late December, as volume has been above average. One block alone of 7.8 million was bought for 125p back a few weeks back The only problem with that is;- if a takeover was on the cards, surely large holders would have been asked for conditional acceptances, and would be trade barred? If that logic is right, then it may not be a takeover but news on US front! Very strange how the news about the 175 takeover was completely snubbed, even if it was baloney you would have expected a rally of some sort on that Telegraph news.
s1zematters
15/1/2018
11:53
Can't see why GSK would even consider buying Vectura, they killed SkyePharma and are doing the same to the combined entity?
aceuk
15/1/2018
11:36
Good post Alex. Best of luck all.
dunderheed
15/1/2018
11:25
diesel-as we are expecting news regarding Advair, it is difficult to know whether the share price rise is simply due to the expectation of good news or whether it is due to a takeover bid in the offing. However, if there were substance to the rumoured 175p bid by GSK, I would expect the share price to be much higher.
alexchry
15/1/2018
10:50
If there is a bid coming that would suggest that the Advair generic stands a good chance of approval.
diesel
15/1/2018
08:52
volsung-does seem that way, volume very high on Friday. DT had Novartis rumours mid December and this month DT suggesting that GSK are preparing a bid. Hard to know whether the rumours are based on information or simply guesswork that the low share price might attract predators.
alexchry
Chat Pages: 260  259  258  257  256  255  254  253  252  251  250  249  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20180118 16:14:22